文献速递垂体与肾上腺疾病性腺与生殖内分泌

21-羟化酶缺陷所致经典型先天性肾上腺皮质增生症管理的未来方向

Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency.
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

本文综述了21-羟化酶缺陷所致经典型先天性肾上腺皮质增生症(21OHD)在诊断和管理方面的改进。11-氧雄激素在21OHD中丰富,其测定可能改善诊断和药物滴定。氢化可的松的昼夜节律给药相比传统糖皮质激素改善了疾病管理;crinecerfont和atumelnant等保糖皮质激素疗法提供了「阻断-替代」策略的潜力,即采用氢化可的松的生理性替代剂量。

要点

  • 11-氧雄激素在21OHD中丰富,其测定可能改善诊断和药物滴定。
  • 氢化可的松昼夜节律给药相比传统糖皮质激素改善21OHD疾病管理。
  • crinecerfont和atumelnant等保糖皮质激素疗法提供「阻断-替代」策略潜力。

核心结论

  • 氢化可的松的昼夜节律给药相比传统糖皮质激素改善了21OHD的疾病管理。
  • crinecerfont和atumelnant等保糖皮质激素疗法提供了「阻断-替代」策略的潜力,即采用氢化可的松的生理性替代剂量。

研究设计与样本

  • 文献综述、综合及作者经验;美国2个中心。

主要发现

  • 11-氧雄激素在21OHD中丰富,其测定可能改善诊断和药物滴定。
  • 多种新疗法正在开发中。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The traditional management of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21OHD) is difficult and often suboptimal. OBJECTIVE: To review improvements in the diagnosis and management of 21OHD. DESIGN: Literature review, synthesis, and authors' experience. SETTING: United States (2 centers). PARTICIPANTS: Not applicable. INTERVENTIONS: Not applicable. MAIN OUTCOMES: Not applicable. RESULTS: The 11-oxygenated androgens are abundant in 21OHD, and their measurement might improve diagnosis and medication titration. Several new treatments are under development. CONCLUSION: Circadian delivery of hydrocortisone improves disease management of 21OHD compared to conventional glucocorticoids. Glucocorticoid-sparing therapies such as crinecerfont and atumelnant offer the potential for a block-and-replace strategy, with physiologic replacement dosing of hydrocortisone. CLINICAL TRIAL REGISTRATION: None.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Sarafoglou K, Auchus RJ. Future Directions in the Management of Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. 2025. PMID: 39836617. doi:10.1210/clinem/dgae759

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。